Welcome to our dedicated page for INVO Bioscience news (Ticker: $INVO), a resource for investors and traders seeking the latest updates and insights on INVO Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INVO Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INVO Bioscience's position in the market.
INVO Bioscience reported record Q1 2024 revenue growth of 353% year-over-year, reaching $1,576,286. Clinic revenue surged 417% to $1,537,199, derived from its Atlanta and Madison IVF centers. The total revenue from all clinics increased 189% to $1,869,513. Operating expenses decreased to $2.5 million, while net loss reduced to $(1.6) million from $(2.6) million. Adjusted EBITDA improved to $(0.5) million from $(1.7) million. The company also highlighted its definitive merger agreement with NAYA Biosciences, where NAYA shareholders will receive 7.3333 shares of INVO for each share of NAYA. The merger is subject to closing conditions, including shareholder approval and a $5 million funding requirement.